RCKT

1.9507.58%
DP

David P. Southwell

Independent Director

Mr. David P. Southwell, M.B.A., serves as Chief Executive Officer of Volastra Therapeutics, Inc. since May 2025 and serves as its Director. He is Executive Chairman of ImmVue Therapeutics Inc. Mr. Southwell is Director of Sensorium Therapeutics, Inc. from September 2023. He has been Independent Director of PTC Therapeutics, Inc. since December 19, 2005. He served as Chief Executive Officer, President and Director of TScan Therapeutics, Inc. since October 2018 until March 27, 2023. He served as the Chief Executive Officer and President of Inotek Pharmaceuticals Corporation since July 2014 until its merger with Rocket Pharmaceuticals in January 2018. He serves as a Consultant of Sepracor, Inc. He is a Partner of BioNevia Inc. He has extensive experience and significant accomplishment in financial strategy, planning and business development. He served as the Chief Financial Officer and Executive Vice President at Human Genome Sciences Inc. since March 22, 2010 until September 2012 and served as its Principal Accounting Officer. He served as an Executive Vice President of Corporate Planning Development and Licensing at Sepracor Inc. from May 2007 to May 20, 2008 and its Executive Vice President from October 1995 to May 20, 2008. He served as the Chief Financial Officer of Sepracor, Inc. from June 1994 to March 2008 and served as its Secretary. He served as the Chief Financial Officer and Executive Vice President of Corporate Planning, Development & Licensing at Sunovion Pharmaceuticals Inc. from July 1994 to May 20, 2008 and from May 2007 to May 20, 2008 respectively. He also served as an Executive Vice President at Sunovion Pharmaceuticals Inc. since October 1995 and also served as its Secretary. He served as the Chief Financial Officer and Senior Vice President of Sepracor, Inc. from July 1994 to October 1995. During his tenure at Sepracor, he advanced through a series of senior management positions with increasing responsibility in finance, corporate planning, development and licensing. He was responsible for in-licensing United States rights to Omnaris and Alvesco from Nycomed and eslicarbazepine from Bial. From August 1984 to July 1986 and from September 1988 to July 1994, he served as an Investment Banker with Lehman Brothers Inc. in various positions within the investment banking division, including in the position of Vice President, prior to his extensive tenure in the biopharmaceutical sector. His career at Lehman included mergers, acquisitions, leveraged buyouts, restructurings and debt and equity financing transactions. While at Lehman, he managed the IPO of Sepracor in September 1991. He served as the Chairman of Biosphere Medical, Inc. from March 2005 to September 2010. He served as a Director of Spero Therapeutics, Inc. since February 1, 2018 until April 25, 2019. He has been a Director of Rocket Pharmaceuticals, Inc. since August 2014. He served as Director of inVentiv Health Inc. since May 26, 2016 and served as Director of Inotek Pharmaceuticals Corporation since August 2014 until its merger with Rocket Pharmaceuticals in January 2018. He served as an Independent Director at THL Credit, Inc. from 2007 to 2016. He serves as a Director of BioNevia and Panel Intelligence, LLC. He served as a Director of Biosphere Medical Inc. from January 1997 to September 2010 and Human Genome Sciences Inc. from July 2008 to March 22, 2010. He is the Head/Chairman of M.B.A. Advisory Board at the Tuck School of Business Administration at Dartmouth College. He serves on the Board of Overseers at Tuck School of Business Administration. He served as a Director of MedPanel, LLC. He has appeared on CNBC, CNN, Bloomberg and other financial T.V. stations. He holds an M.B.A. from the Tuck School of Business Administration at Dartmouth College and a B.A. in economics and Managerial studies from Rice University.

Positions